^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PSMA-targeted antibody-drug conjugate

    Related drugs:
    11d
    Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3- and PSMA-Directed Bispecific Antibody-Drug Conjugate, for the Treatment of Prostate Cancer. (PubMed, Mol Cancer Ther)
    The compelling preclinical efficacy across cancer models with varying levels of target antigen expression and its exceptional plasma stability support the translational relevance of GenSci143. These results indicate that GenSci143 is a promising therapeutic candidate for castration resistant PCa and potentially other malignancies, warranting its further clinical development.
    Preclinical • Journal
    |
    CD276 (CD276 Molecule)
    2ms
    A Study of DXC014 in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=150, Recruiting, Hangzhou DAC Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Mar 2026
    Enrollment open • Trial initiation date • First-in-human
    2ms
    A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors (clinicaltrials.gov)
    P1/2, N=326, Not yet recruiting, RemeGen Co., Ltd.
    New P1/2 trial
    |
    misitatug blivedotin (RC88)
    2ms
    A Study of MHB048C in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Minghui Pharmaceutical (Hangzhou) Ltd | Initiation date: Oct 2025 --> Jan 2026
    Trial initiation date • First-in-human
    2ms
    A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=230, Recruiting, AbbVie | N=36 --> 230
    Enrollment change • Adverse events • First-in-human
    4ms
    APEX-01: ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=183, Active, not recruiting, Janssen Research & Development, LLC | N=50 --> 183
    Enrollment change • First-in-human
    |
    FOLH1 positive
    |
    abiraterone acetate • prednisone • apalutamide • JNJ-8177
    4ms
    A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer (clinicaltrials.gov)
    P1/2, N=180, Recruiting, T.O.A.D. Oncology SA | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    FOLH1 expression
    4ms
    APEX-01: ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=183 --> 50 | Trial completion date: Dec 2028 --> Dec 2026 | Trial primary completion date: Jun 2027 --> Dec 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    FOLH1 positive
    |
    abiraterone acetate • prednisone • apalutamide • JNJ-8177
    4ms
    TD001-101: A first-in-human study to determine a safe dose of the drug TD001 to treat patients with metastatic prostate cancer that expresses the PSMA protein. (2025-523273-41-00)
    P1/2, N=110, Recruiting, T.O.A.D. Oncology S.A.
    New P1/2 trial • First-in-human
    |
    HRD (Homologous Recombination Deficiency)
    4ms
    A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer (clinicaltrials.gov)
    P1, N=140, Recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2027 --> Mar 2027 | Trial primary completion date: Sep 2027 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    AR (Androgen receptor)
    |
    JNJ-8177 • pasritamig (JNJ-8343)
    5ms
    GenSci143 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=180, Recruiting, Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    6ms
    A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer (clinicaltrials.gov)
    P1/2, N=180, Not yet recruiting, T.O.A.D. Oncology SA
    New P1/2 trial